Middle East And Africa Hla Typing Transplant Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2021 –2028 |
 Market Size (Base Year) |
USD 14.48 Million |
 Market Size (Forecast Year) |
USD 21.50 Million |
 CAGR |
% |
| Major Markets Players |
>中东和非洲移植市场人类白细胞抗原 (HLA) 分型，产品和服务（试剂和消耗品、仪器、软件和服务）、技术（基于测序的分子测定、分子测定技术、非分子测定技术）、移植类型（实体器官移植、造血干细胞移植）、应用（诊断应用、研究应用）、最终用户（独立参考实验室、医院和移植中心、研究实验室和学术机构）、国家（南非和中东及非洲其他地区）行业趋势和预测到 2028 年。
市场分析和洞察：中东和非洲移植市场的人类白细胞抗原 (HLA) 分型
预计在 2021 年至 2028 年的预测期内，中东和非洲的人类白细胞抗原 (HLA) 分型移植市场将实现显着增长。Data Bridge Market Research 分析，在 2021 年至 2028 年的预测期内，中东和非洲的人类白细胞抗原 (HLA) 分型移植市场将以 5.5% 的复合年增长率增长，预计到 2028 年将从 2020 年的 1448 万美元增至 2150 万美元。对器官移植程序的需求不断增长，推动了人类白细胞分型移植市场的增长。
人类白细胞抗原 (HLA) 分型用于匹配患者和骨髓或脐带血移植的捐赠者。HLA 是存在于体内大多数细胞中的蛋白质（或标记物）。免疫系统利用这些标记物来识别哪些细胞属于身体，哪些细胞不属于身体。
研究发现，捐赠者必须至少匹配 6 个 HLA 标记。很多时候需要更接近的匹配。通过详细测试可以找到最佳匹配。由于某些 HLA 类型比其他类型更常见，因此一些患者在寻找匹配的捐赠者时可能面临更大的挑战。某些 HLA 类型在某些种族和民族群体中更常见。
捐献者和患者的 HLA 标记紧密匹配对于移植成功至关重要。HLA 匹配可促进新的健康血细胞的生长和发育（称为植入），并降低移植后并发症（称为移植物抗宿主病 (GVHD)）的风险。
器官捐赠的高需求、不断增长的创新和技术以及新产品的推出也推动了中东和非洲人类白细胞抗原 (HLA) 分型移植市场的增长。
越来越多的人受到 HLA 疾病的影响，需要高效和先进的治疗以尽量降低治疗过程中的风险。医疗保健系统在治疗患者时需要针对多种不同类型的 HLA 疾病的先进药物。因此，主要市场参与者高度关注产品发布和产品批准。此外，政府和监管机构通过产品批准为市场参与者提供支持。
不断增加的产品发布为这个市场带来了机遇，预计将推动市场增长，从而促进全球人类白细胞分型移植市场的需求。
人类白细胞抗原 (HLA) 是一种广泛研究的与免疫有关的分子，NGS 技术通过提供快速且经济高效的技术彻底改变了 HLA 分型程序。预计缺乏熟练的专业人员是全球移植用人类白细胞抗原 (HLA) 分型市场未来增长的主要挑战。
中东和非洲人类白细胞抗原 (HLA) 移植市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息，分析了新兴收入领域、市场法规变化、产品批准、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情况，请联系我们获取分析师简报，我们的团队将帮助您创建收入影响解决方案以实现您的期望目标。
中东和非洲人类白细胞抗原 (HLA) 分型移植市场 及市场规模
中东和非洲移植用人类白细胞抗原 (HLA) 分型市场根据产品和服务、技术、移植类型、应用和最终用户进行细分。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
- 根据产品和服务，中东和非洲移植用人类白细胞抗原 (HLA) 分型市场细分为试剂和耗材、仪器、软件和服务。2021 年，由于主要市场参与者推出的产品不断增加，预计仪器部分将占据市场主导地位。
- 从技术角度来看，中东和非洲移植市场中的人类白细胞抗原 (HLA) 分型包括分子检测技术和非分子检测技术。2021 年，分子检测技术领域预计将占据市场主导地位，因为它是最有效的管理模式。
- 根据移植类型，中东和非洲移植市场的人类白细胞抗原 (HLA) 分型分为实体器官移植和造血干细胞移植。2021 年，由于目标人群的认知度不断提高，实体器官移植领域预计将占据市场主导地位。
- 根据应用，中东和非洲移植用人类白细胞抗原 (HLA) 分型市场分为诊断应用和研究应用。2021 年，诊断应用领域预计将占据市场主导地位，因为 HLA 分型方面的研发活动不断增加，例如 NGS 测序应用，这推动了移植用人类白细胞抗原 (HLA) 分型市场的研究应用。
- 根据最终用户，中东和非洲移植用人类白细胞抗原 (HLA) 分型市场分为独立参考实验室、医院和移植中心、研究实验室和学术机构。由于政府资金增加，预计 2021 年医院和移植中心将占据市场主导地位。
中东和非洲人类白细胞抗原 (HLA) 分型移植市场国家级分析
对中东和非洲移植市场的人类白细胞抗原 (HLA) 分型进行了分析，并根据国家、产品和服务、技术、移植类型、应用和最终用户提供了市场规模信息。
中东和非洲移植市场人类白细胞抗原 (HLA) 分型报告涵盖的国家包括南非和中东和非洲的其他地区。
由于该地区政府资金的增加，南非有望在中东和非洲人类白细胞抗原 (HLA) 分型移植市场中占据主导地位。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了中东和非洲品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战、销售渠道的影响。
中东和非洲人类白细胞抗原 (HLA) 分型移植市场的医疗支出不断增长，创新和技术不断升级，为中东和非洲人类白细胞抗原 (HLA) 分型移植市场的参与者创造了新的机会
中东和非洲人类白细胞抗原 (HLA) 分型移植市场还为您提供了每个国家/地区特定行业的详细市场分析，包括中东和非洲人类白细胞抗原 (HLA) 分型移植市场销售的增长情况、中东和非洲人类白细胞抗原 (HLA) 分型移植市场发展的影响以及监管情景的变化及其对 2011 年至 2019 年期间中东和非洲人类白细胞抗原 (HLA) 分型移植市场的支持。
竞争格局和中东和非洲移植用人类白细胞抗原 (HLA) 分型市场份额分析
中东和非洲人类白细胞抗原 (HLA) 移植市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势和技术生命线曲线。以上提供的数据点仅与公司对中东和非洲人类白细胞抗原 (HLA) 移植市场的关注有关。
报告中涉及的主要参与者包括 Thermo Fisher Scientific Inc.、Illumina, Inc.、Luminex Corporation、QIAGEN、CareDX, Inc.、Immucor Inc.、Bio Rad Labaratories, Inc.、Takara Bio Inc.、BD、Fujirebio、TBG Diagnostics Limited 和 GenDx。
DBMR 分析师了解竞争优势并为每个竞争对手分别提供竞争分析。
全球各地的公司也推出了许多产品并达成了多项协议，进一步加速了中东和非洲人类白细胞抗原 (HLA) 分型移植市场的发展。
例如，
- 2017 年 10 月，TBG 的 HLAssure SE SBT 试剂盒获得中国国家食品药品监督管理局临床使用批准。这是中国首次批准高分辨率 HLA 分型试剂盒。这有助于该公司加强其在中国的业务并促进市场增长
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT & SERVICES LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 AVERAGE PRICE/TEST FOR HLA TYPING BY NEXT GENERATION SEQUENCING (USD)
4.2 PESTEL'S MODEL
4.3 PORTER'S 5 FORCES
5 REGIONAL SUMMARY
5.1 MIDDLE EAST AND AFRICA
5.1.1 OVERVIEW
6 REGULATORY GUIDELINES FOR MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) FOR TRANSPLANT MARKET
6.1 U.S.
6.2 EUROPE
6.3 JAPAN
6.4 INDIA
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING DEMAND FOR ORGAN TRANSPLANT PROCEDURES
7.1.2 GROWING TECHNOLOGICAL ADVANCEMENT & INNOVATIONS IN HLA TYPING
7.1.3 RISING RESEARCH AND DEVELOPMENT ACTIVITIES IN HLA TYPING
7.1.4 INCREASING CERTAIN DISEASES SUCH AS BLOOD CANCERS, AND GENETIC BLOOD DISORDERS
7.2 RESTRAINTS
7.2.1 HIGH COST OF HLA TYPING FOR TRANSPLANTATION PROCEDURE
7.2.2 LIMITED REIMBURSEMENTS POLICIES FOR ORGAN TRANSPLANT
7.3 OPPORTUNITIES
7.3.1 PRODUCT LAUNCHES, AND AGREEMENT BY MAJOR PLAYERS
7.3.2 RISING GOVERNMENT FUNDING FOR ORGAN DONATIONS
7.3.3 RISING PUBLIC AWARENESS FOR ORGAN TRANSPLANTATION
7.4 CHALLENGES
7.4.1 LESS NUMBER OF DONORS FOR ORGAN DONATION
7.4.2 DEARTH OF SKILLED PROFESSIONALS
8 COVID-19 IMPACT ON HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET
8.1 IMPACT ON PRICE
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISIONS FOR MANUFACTURERS
8.5 CONCLUSION
9 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES
9.1 OVERVIEW
9.2 INSTRUMENTS
9.3 REAGENTS AND CONSUMABLES
9.4 SOFTWARE & SERVICES
10 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY
10.1 OVERVIEW
10.2 MOLECULAR ASSAY TECHNOLOGIES
10.2.1 SEQUENCING-BASED MOLECULAR ASSAYS
10.2.1.1 NEXT-GENERATION SEQUENCING
10.2.1.2 SANGER SEQUENCING
10.2.1.3 OTHER SEQUENCING-BASED MOLECULAR ASSAYS
10.2.2 PCR-BASED MOLECULAR ASSAYS
10.2.2.1 SEQUENCE-SPECIFIC PRIMER-PCR
10.2.2.2 REAL-TIME PCR
10.2.2.3 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR
10.2.2.4 OTHER PCR-BASED MOLECULAR ASSAYS
10.3 NON-MOLECULAR ASSAY TECHNOLOGIES
11 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE
11.1 OVERVIEW
11.2 SOLID ORGAN TRANSPLANT
11.2.1 KIDNEY
11.2.2 LIVER
11.2.3 HEART
11.2.4 LUNG
11.2.5 PANCREAS
11.2.6 OTHERS
11.3 HEMATOPOIETIC STEM CELL TRANSPLANT
11.3.1 STEM CELL TRANSPLANT
11.3.2 BONE MARROW TRANSPLANT
12 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 DIAGNOSTIC APPLICATIONS
12.2.1 ANTIBODY SCREENING
12.2.2 CHIMERISM MONITORING
12.2.3 OTHERS
12.3 RESEARCH APPLICATIONS
13 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS & TRANSPLANT CENTERS
13.3 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
13.4 INDEPENDENT REFERENCE LABORATORIES
14 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION
14.1 MIDDLE EAST AND AFRICA
14.1.1 SOUTH AFRICA
14.1.2 REST OF MIDDLE EAST AND AFRICA
15 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
16 MARKET SHARE ANALYSIS: BY TECHNOLOGY
16.1 SEQUENCING BASED MOLECULAR ASSAYS
16.1.1 NORTH AMERICA
16.1.2 EUROPE
16.1.3 ASIA-PACIFIC
16.1.4 SOUTH AMERICA
16.1.5 MIDDLE EAST AND AFRICA
16.2 NGS SEQUENCING
16.2.1 NORTH AMERICA
16.2.2 EUROPE
16.2.3 ASIA-PACIFIC
16.2.4 SOUTH AMERICA
16.2.5 MIDDLE EAST AND AFRICA
16.3 SANGER SEQUENCING
16.3.1 NORTH AMERICA
16.3.2 EUROPE
16.3.3 ASIA-PACIFIC
16.3.4 SOUTH AMERICA
16.3.5 MIDDLE EAST AND AFRICA
16.4 PCR BASED MOLECULAR ASSAYS
16.4.1 NORTH AMERICA
16.4.2 EUROPE
16.4.3 ASIA-PACIFIC
16.4.4 SOUTH AMERICA
16.4.5 MIDDLE EAST AND AFRICA
16.5 REAL TIME PCR
16.5.1 NORTH AMERICA
16.5.2 EUROPE
16.5.3 ASIA-PACIFIC
16.5.4 SOUTH AMERICA
16.5.5 MIDDLE EAST AND AFRICA
16.6 SEQUENCE-SPECIFIC PRIMER-PCR
16.6.1 NORTH AMERICA
16.6.2 EUROPE
16.6.3 ASIA-PACIFIC
16.6.4 SOUTH AMERICA
16.6.5 MIDDLE EAST AND AFRICA
16.7 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR
16.7.1 NORTH AMERICA
16.7.2 EUROPE
16.7.3 ASIA-PACIFIC
16.7.4 SOUTH AMERICA
16.7.5 MIDDLE EAST AND AFRICA
17 COMPANY PROFILE
17.1 THERMO FISHER SCIENTIFIC INC.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.1.6 SWOT ANALYSIS
17.2 ILLUMINA, INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.2.6 SWOT ANALYSIS
17.3 BIO-RAD LABORATORIES, INC.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.3.6 SWOT ANALYSIS
17.4 QIAGEN
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS
17.4.5.1 ACQUISITION
17.4.6 SWOT ANALYSIS
17.5 ROCHE SEQUENCING (A SUBSIDIARY OF F.HOFFMAN LA-ROCHE LTD.)
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.5.6 SWOT ANALYSIS
17.6 BD
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENTS
17.7 BIOFORTUNA LIMITED
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENT
17.8 CARE DX, INC.
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENTS
17.9 CREATIVE BIOLABS
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.9.3.1 PRODUCT LAUNCH/UPDATE/APPROVAL
17.1 FUJIREBIO
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.10.4.1 CE CERTIFICATION
17.11 GENDX
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENTS
17.12 IMMUCOR, INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.12.3.1 PROUCT LAUNCH
17.13 LUMINEX CORPORATION
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENTS
17.14 OMIXON INC.
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.14.3.1 PRODUCT LAUNCH
17.15 TAKARA BIO INC
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENTS
17.15.4.1 LICENSING
17.15.5 PRODUCT LAUNCH
17.16 TBG DIAGNOSTICS LIMITED
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
表格列表
TABLE 1 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, AVERAGE PRICE/TEST FOR HLA TYPING BY NEXT GENERATION SEQUENCING
TABLE 2 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BYPRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA INSTRUMENTS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA REAGENTS AND CONSUMABLES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA SOFTWARE & SERVICES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY , 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY , 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA NON-MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE , 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, REGION, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA RESEARCH APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA HOSPITALS & TRANSPLANT CENTERS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA RESEARCH LABORATORIES & ACADEMIC INSTITUTES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA OTHERS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 37 SOUTH AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 38 SOUTH AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 39 SOUTH AFRICA MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 40 SOUTH AFRICA SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 41 SOUTH AFRICA PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 42 SOUTH AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 43 SOUTH AFRICA SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 44 SOUTH AFRICA HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 45 SOUTH AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 46 SOUTH AFRICA DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 47 SOUTH AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 48 REST OF MIDDLE EAST AND AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
图片列表
FIGURE 1 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET:
FIGURE 3 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: SEGMENTATION
FIGURE 11 INCREASING DEMAND FOR ORGAN TRANSPLANTATION, AND RISING R&D ACTIVITIES IN HLA TYPING ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, AND ASIA-PACIFIC EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET
FIGURE 15 IN 2021, ESTIMATED NEW CASES OF LEUKEMIA, MYELOMA, AND LYMPHOMA IN THE U.S.
FIGURE 16 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, 2020
FIGURE 17 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, 2021-2028 (USD MILLION)
FIGURE 18 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, CAGR (2021-2028)
FIGURE 19 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, LIFELINE CURVE
FIGURE 20 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, 2020
FIGURE 21 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, 2021-2028 (USD MILLION)
FIGURE 22 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, CAGR (2021-2028)
FIGURE 23 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 24 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, 2020
FIGURE 25 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, 2021-2028 (USD MILLION)
FIGURE 26 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, CAGR (2021-2028)
FIGURE 27 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, LIFELINE CURVE
FIGURE 28 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, 2020
FIGURE 29 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, 2021-2028 (USD MILLION)
FIGURE 30 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 31 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 32 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY END USERS, 2021-2028 (USD MILLION)
FIGURE 33 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY END USERS, CAGR (2021-2028)
FIGURE 34 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: END USERS, CAGR (2021-2028)
FIGURE 35 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY END USERS, LIFELINE CURVE
FIGURE 36 MIDDLE EAST AND AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: SNAPSHOT (2020)
FIGURE 37 MIDDLE EAST AND AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY COUNTRY (2020)
FIGURE 38 MIDDLE EAST AND AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 39 MIDDLE EAST AND AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY COUNTRY (2020 & 2028)
FIGURE 40 MIDDLE EAST AND AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCT & SERVICES (2021-2028)
FIGURE 41 MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: COMPANY SHARE 2020 (%)
FIGURE 42 NORTH AMERICA SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 43 EUROPE SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 44 ASIA-PACIFIC SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 45 SOUTH AMERICA SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 46 MIDDLE EAST AND AFRICA SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 47 NORTH AMERICA NGS SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 48 EUROPE NGS SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 49 ASIA-PACIFIC NGS SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 50 SOUTH AMERICA NGS SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 51 MIDDLE EAST AND AFRICA NGS SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 52 NORTH AMERICA SANGER SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 53 EUROPE SANGER SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 54 ASIA-PACIFIC SANGER SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 55 SOUTH AMERICA SANGER SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 56 MIDDLE EAST AND AFRICA SANGER SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 57 NORTH AMERICA PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 58 EUROPE PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 59 ASIA-PACIFIC PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 60 SOUTH AMERICA PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 61 MIDDLE EAST AND AFRICA PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 62 NORTH AMERICA REAL TIME PCR: COMPANY SHARE 2020 (%)
FIGURE 63 EUROPE REAL TIME PCR: COMPANY SHARE 2020 (%)
FIGURE 64 ASIA-PACIFIC REAL TIME PCR: COMPANY SHARE 2020 (%)
FIGURE 65 SOUTH AMERICA REAL TIME PCR: COMPANY SHARE 2020 (%)
FIGURE 66 MIDDLE EAST AND AFRICA REAL TIME PCR: COMPANY SHARE 2020 (%)
FIGURE 67 NORTH AMERICA SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)
FIGURE 68 EUROPE SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)
FIGURE 69 ASIA-PACIFIC SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)
FIGURE 70 SOUTH AMERICA SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)
FIGURE 71 MIDDLE EAST AND AFRICA SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)
FIGURE 72 NORTH AMERICA SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)
FIGURE 73 EUROPE SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)
FIGURE 74 ASIA-PACIFIC SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)
FIGURE 75 SOUTH AMERICA SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)
FIGURE 76 MIDDLE EAST AND AFRICA SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
